初治前列腺癌患者淋巴结受累:280例放疗管理人群PSMA PET/CT与Roach公式的相关性
本研究纳入280例新诊断前列腺癌患者,均行PSMA PET/CT用于初治分期,其中84%按d'Amico标准为高危。PSMA阳性淋巴结见于90/280例(32.1%),36.0%的淋巴结转移位于盆腔外,9例(3.2%)累及Virchow淋巴结;Roach公式预测淋巴结受累的AUC为0.781。结论认为PSMA PET/CT适合检测淋巴结转移,而原始Roach公式仍可用于日常临床中快速评估潜在淋巴播散风险。
要点
- 280例初治前列腺癌中PSMA PET/CT检出淋巴结转移90例(32.1%)。
- 淋巴结转移中36.0%位于盆腔外,9例(3.2%)累及Virchow淋巴结。
- Roach公式预测淋巴结受累的AUC为0.781。
核心结论
- 对初治前列腺癌患者,PSMA PET/CT适合用于检测淋巴结转移。
- 原始Roach公式仍可用于日常临床中快速评估潜在淋巴播散。
研究设计与样本
- 研究纳入280例新诊断前列腺癌患者,均行PSMA PET/CT进行初治分期。
- 患者中位年龄67岁(范围38-84岁),84%按d'Amico标准归为高危。
- 以Roach公式计算淋巴结受累风险,并与PSMA PET/CT结果进行比较。
主要发现
- 280例中90例(32.1%)检出PSMA阳性淋巴结。
- 多数淋巴结转移位于盆腔,但36.0%位于盆腔外。
- 9例(3.2%)淋巴结转移位于Virchow淋巴结。
- Roach公式预测淋巴结受累的AUC为0.781。
关键数值与推荐
- PSMA阳性淋巴结检出率为32.1%(90/280)。
- 盆腔外淋巴结转移占36.0%,Virchow淋巴结转移占3.2%(9例)。
- Roach公式预测淋巴结受累的AUC为0.781。
临床怎么用
- 初治前列腺癌分期可行PSMA PET/CT以检测淋巴结转移,包括盆腔外站点。
- 日常临床中可用原始Roach公式快速评估潜在淋巴播散风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The importance of prostate-specific membrane antigen (PSMA) PET/CT for primary staging of treatment-naïve prostate cancer patients is still under debate. Therefore, the present study aimed to evaluate the role of PSMA PET/CT in detecting nodal metastases in a large cohort of men and compare imaging results with the risk of lymph node involvement based on the Roach formula. Methods: In total, 280 men with newly diagnosed prostate carcinoma were included in the present study. For all patients, PSMA PET/CT was performed for primary staging. Median age was 67 y (range, 38-84 y), and 84% of all patients were classified as high-risk according to the d'Amico criteria. The risk of lymph node involvement was calculated using the Roach formula and compared with the PSMA PET/CT results. Results: PSMA-positive nodes were detected in 90 of 280 men (32.1%). Although most nodal metastases occurred within the pelvis, 36.0% were in extrapelvic sites. In 9 patients (3.2%), nodal metastases occurred in the Virchow node. After comparison of PSMA data with the results of the Roach formula, an area under the curve of 0.781 was obtained for the Roach predictions. Conclusion: For treatment-naïve prostate cancer patients, PSMA PET/CT is well suited for the detection of nodal metastases. However, the original Roach formula can still be used for a quick assessment of potential lymphatic spread in daily clinical routine.
引用
- Koerber SA, Stach G, Kratochwil C, et al. Lymph Node Involvement in Treatment-Naïve Prostate Cancer Patients: Correlation of PSMA PET/CT Imaging and Roach Formula in 280 Men in Radiotherapeutic Management. J Nucl Med. 2019. PMID: 31302638. doi:10.2967/jnumed.119.227637
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。